Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/17/2025 | $44.00 | Overweight | Analyst |
| 12/17/2024 | $18.00 | Overweight → Neutral | Analyst |
| 11/6/2024 | $40.00 | Overweight | JP Morgan |
| 10/9/2024 | $50.00 | Buy | UBS |
| 9/11/2024 | $45.00 | Buy | Citigroup |
| 6/28/2024 | $35.00 | Outperform | Macquarie |
Analyst resumed coverage of PACS Group with a rating of Overweight and set a new price target of $44.00
Analyst downgraded PACS Group from Overweight to Neutral and set a new price target of $18.00
JP Morgan resumed coverage of PACS Group with a rating of Overweight and set a new price target of $40.00
Former CMS Deputy Administrator, Chief Medical Officer, and Current CEO of Optum Brings Unparalleled Clinical, Regulatory, and Healthcare Leadership to PACS Board PACS Group, Inc. (NYSE:PACS), one of the nation's largest and fastest-growing post-acute healthcare platforms, today announced the appointment of Patrick H. Conway, MD, MSc, to its Board of Directors. Dr. Conway's addition to the PACS Board represents a landmark appointment for the post-acute and skilled nursing industry — bringing to the boardroom a rare combination of hands-on clinical experience, transformative federal regulatory leadership, large-scale health system executive experience, and deep expertise in quality, value-
Conference Call and Webcast Scheduled for Today, February 26, 2026, at 5:30 pm ET. PACS Group, Inc. (NYSE:PACS) ("PACS" or the "Company"), which together with its subsidiaries is one of the largest post-acute healthcare companies in the United States, announced operating results for the fiscal year and fourth quarter of 2025. Full Year 2025 Financial Highlights Revenue was $5.29 billion, an increase of 29.3% over prior year. Net income was $191.5 million. Adjusted EBITDA was $505.0 million. Adjusted EBITDAR was $883.9 million. Fourth Quarter 2025 Financial Highlights Revenue was $1.36 billion, an increase of 12.4% over the same period prior year. Net income was $59.
PACS Group, Inc. (NYSE:PACS) ("PACS" or the "Company"), which together with its subsidiaries is one of the largest post-acute healthcare companies in the United States, today announced that it intends to release its fiscal year and fourth quarter 2025 financial results after market close on Thursday, February 26, 2026. Management will host a call on Thursday, February 26, 2026, at 5:30 p.m. ET to discuss the financial results and related information. PACS Group invites current and prospective investors to listen to the call via webcast by going to the Investors section of the PACS Group website at https://ir.pacs.com/ or https://event.choruscall.com/mediaframe/webcast.html?webcastid=kswnl
4 - PACS Group, Inc. (0002001184) (Issuer)
3 - PACS Group, Inc. (0002001184) (Issuer)
4 - PACS Group, Inc. (0002001184) (Issuer)
8-K - PACS Group, Inc. (0002001184) (Filer)
8-K - PACS Group, Inc. (0002001184) (Filer)
8-K - PACS Group, Inc. (0002001184) (Filer)
4 - PACS Group, Inc. (0002001184) (Issuer)
SC 13G - PACS Group, Inc. (0002001184) (Subject)
SC 13G - PACS Group, Inc. (0002001184) (Subject)
SC 13G - PACS Group, Inc. (0002001184) (Subject)
Conference Call and Webcast Scheduled for Today, February 26, 2026, at 5:30 pm ET. PACS Group, Inc. (NYSE:PACS) ("PACS" or the "Company"), which together with its subsidiaries is one of the largest post-acute healthcare companies in the United States, announced operating results for the fiscal year and fourth quarter of 2025. Full Year 2025 Financial Highlights Revenue was $5.29 billion, an increase of 29.3% over prior year. Net income was $191.5 million. Adjusted EBITDA was $505.0 million. Adjusted EBITDAR was $883.9 million. Fourth Quarter 2025 Financial Highlights Revenue was $1.36 billion, an increase of 12.4% over the same period prior year. Net income was $59.
PACS Group, Inc. (NYSE:PACS) ("PACS" or the "Company"), which together with its subsidiaries is one of the largest post-acute healthcare companies in the United States, today announced that it intends to release its fiscal year and fourth quarter 2025 financial results after market close on Thursday, February 26, 2026. Management will host a call on Thursday, February 26, 2026, at 5:30 p.m. ET to discuss the financial results and related information. PACS Group invites current and prospective investors to listen to the call via webcast by going to the Investors section of the PACS Group website at https://ir.pacs.com/ or https://event.choruscall.com/mediaframe/webcast.html?webcastid=kswnl
PACS Group, Inc. (NYSE:PACS) ("PACS" or the "Company") today announced that independently operated subsidiaries of the Company have acquired the operations of three post-acute care facilities, two located in Alaska and one in Idaho, representing a total of 230 beds. The facilities are located in the Kenai Peninsula region of Alaska and the Boise metropolitan area of Idaho. The Company acquired the real estate associated with the two Alaska facilities, while the Idaho facility will operate under a lease arrangement with a third-party landlord. In addition, PACS recently acquired the real estate for two existing skilled nursing operations: Sierra Valley Rehab Center in Porterville, Californ
Former CMS Deputy Administrator, Chief Medical Officer, and Current CEO of Optum Brings Unparalleled Clinical, Regulatory, and Healthcare Leadership to PACS Board PACS Group, Inc. (NYSE:PACS), one of the nation's largest and fastest-growing post-acute healthcare platforms, today announced the appointment of Patrick H. Conway, MD, MSc, to its Board of Directors. Dr. Conway's addition to the PACS Board represents a landmark appointment for the post-acute and skilled nursing industry — bringing to the boardroom a rare combination of hands-on clinical experience, transformative federal regulatory leadership, large-scale health system executive experience, and deep expertise in quality, value-